U.S. markets closed
  • S&P 500

    3,269.96
    -40.15 (-1.21%)
     
  • Dow 30

    26,501.60
    -157.51 (-0.59%)
     
  • Nasdaq

    10,911.59
    -274.00 (-2.45%)
     
  • Russell 2000

    1,538.48
    -23.10 (-1.48%)
     
  • Crude Oil

    35.72
    -0.45 (-1.24%)
     
  • Gold

    1,878.80
    +10.80 (+0.58%)
     
  • Silver

    23.72
    +0.35 (+1.52%)
     
  • EUR/USD

    1.1641
    -0.0037 (-0.31%)
     
  • 10-Yr Bond

    0.8600
    +0.0250 (+2.99%)
     
  • GBP/USD

    1.2953
    +0.0030 (+0.23%)
     
  • USD/JPY

    104.6350
    +0.0250 (+0.02%)
     
  • BTC-USD

    13,729.49
    -96.82 (-0.70%)
     
  • CMC Crypto 200

    265.42
    +1.78 (+0.68%)
     
  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Regeneron is Trump's COVID-19 treatment: What to know

FoxBusiness.com
·2 mins read

President Trump's physician is treating his COVID-19 with Rengeron's experimental treatment. The details were released as the President makes his way to Walter Reed National Military Medical Center for observation.

Regeneron confirmed it has released the drug under the "Compassionate Use Request" in which the Food & Drug Administration permits usage to those, not in clinical trials, according to the Mayo Clinic. Normally, this process is long and challenging.

A year ago, this biotech company was known mainly to health care investors and the medical community now it's on the cusp of potentially treating the millions infected with the coronavirus.

FOX Business has more on the business behind the company.

Regeneron Stock

The company, which is headquartered in Tarrytown, New York, went public in 1991 at $22 per share. Today, the stock is trading around $565 per share, as it races towards a treatment for COVID-19. The company has 7 FDA approved drugs and 20 in the pipeline, according to company documents.

Shares have gained over 50% this year.

TRUMP'S COVID-19 POSITIVE TESTS GIVES WALL ST. A WILD RIDE

Regeneron's Big Investors

The company's largest institutional holders of the stock, as tracked by Thomson One, include the two largest U.S. mutual fund companies Fidelity and Vanguard which hold 11.5% and 7.5% respectively, of company shares.

The largest individual stockholder is Co-Founder, President and Chief Scientific Officer George D. Yancopoulos, MD, PhD who holds 1.06% of outstanding shares.

The company has 8,000 employees.

Regeneron's Board of Directors

This biotech's board boasts a Nobel Laureates and a former Wall Street CEO.

Art Ryan rose to prominence running Prudential Financial until he retired in 2008.

And Michael Brown, jointly received the Nobel Prize for Physiology or Medicine in 1985 with Dr. Joseph Goldstein, who is not a board member. Brown is now Regental Professor of Molecular Genetics and Internal Medicine, Director, Erik Jonsson Center for Molecular Genetics, The University of Texas Southwestern Medical Center at Dallas.

KUDLOW, MNUCHIN, ROSS TEST NEGATIVE FOR COVID-19

COVID-19 Experimental Treatment

In late September, the company said its antibody cocktail was successful in treating common COVID-19 symptoms.

"After months of incredibly hard work by our talented team, we are extremely gratified to see that Regeneron's antibody cocktail REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron in the company's press release.

Following Trump's disclosure, he and first lady Melania had tested positive...

Some physicians including Dr. Matt McCarthy, an infectious disease expert, identified Regeneron's drug as the best option for treatment at this time.

Related Articles